Kristina Sonnevi

Publikationer
CV
Populärvetenskap och samverkan

Utvalda publikationer

Article: LEUKEMIA & LYMPHOMA. 2024;65(4):534-537

Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.

Harrysson S; Eloranta S; Ekberg S; Enblad G; Andersson P-O; Sonnevi K; Ljungqvist M; Sander B; Jerkeman M; Smedby KE

Artiklar

Article: LEUKEMIA. 2024;38(3):610-620

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.

Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini R-M; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Article: BLOOD ADVANCES. 2024;8(2):407-415

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
Article: EJHAEM. 2023;4(3):647-655

Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

Junlén H-R; Sonnevi K; Lindén O; Hellström M; Scivetti MV; Olsson M; Tufvesson I; Johansson A-S; Wahlin BE
Article: HEMASPHERE. 2023;7(8):e928

Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project.

Jerkeman M; Ekberg S; Glimelius I; Albertsson-Lindblad A; Entrop JP; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Article: ISCIENCE. 2023;26(6):106864

ADAR1-mediated RNA editing promotes B cell lymphomagenesis.

Pecori R; Ren W; Pirmoradian M; Wang X; Liu D; Berglund M; Li W; Tasakis RN; Di Giorgio S; Ye X; Li X; Arnold A; Wüst S; Schneider M; Selvasaravanan K-D; Fuell Y; Stafforst T; Amini R-M; Sonnevi K; Enblad G; Sander B; Wahlin BE; Wu K; Zhang H; Helm D; Binder M; Papavasiliou FN; Pan-Hammarström Q
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):429-430

Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapies

Smedby KE; Antonilli S; Enblad G; Sonnevi K; Wahlin BE; Andersson P; Jerkeman M; Eloranta S
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):476-477

How to choose between curative radiotherapy or chemotherapy in low stage MCL?—a population‐based analysis of outcome in patients with stage I‐II MCL in Sweden

Albertsson‐Lindblad A; Ekberg S; Glimelius I; Ellin F; Sonnevi K; Lewerin C; Smedby KE; Jerkeman M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):302-303

Genetic and transcriptomic analyses of diffuse large B‐cell lymphoma patients with poor outcomes within two years of diagnosis

Ren W; Own SA; Wan H; Berglund M; Wang X; Yang M; Li X; Liu D; Sonnevi K; Enblad G; Amini R; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan‐Hammarström Q
Article: CANCERS. 2023;15(5):1585

2-Arachidonoylglycerol Modulates CXCL12-Mediated Chemotaxis in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia.

Merrien M; Wasik AM; Melén CM; Morsy MHA; Sonnevi K; Junlén H-R; Christensson B; Wahlin BE; Sander B
Article: FRONTIERS IN ONCOLOGY. 2023;13:1176698

Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.

Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(2):267-277

Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.

Harrysson S; Eloranta S; Ekberg S; Enblad G; El-Galaly TC; Sander B; Sonnevi K; Andersson P-O; Jerkeman M; Smedby KE
Article: LEUKEMIA & LYMPHOMA. 2022;63(6):1387-1397

Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.

Melén CM; Merrien M; Wasik AM; Panagiotidis G; Beck O; Sonnevi K; Junlén H-R; Christensson B; Sander B; Wahlin BE
Article: EJHAEM. 2021;2(4):774-784

Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience.

Sonnevi K; Ljungqvist M; Jóelsson JK; Harrysson S; Wästerlid T; Bernell P; Wahlin BE
Article: BMC CANCER. 2021;21(1):500

The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.

Noring K; Carlsten M; Sonnevi K; Wahlin BE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(1):75-81

Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.

Sonnevi K; Wästerlid T; Melén CM; Harrysson S; Smedby KE; Wahlin BE
Article: HEMASPHERE. 2021;5(1):e510

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.

Eskelund CW; Dimopoulos K; Kolstad A; Glimelius I; Räty R; Gjerdrum LMR; Sonnevi K; Josefsson P; Nilsson-Ehle H; Bentzen HHN; Fagerli UM; Kuittinen O; Haaber J; Niemann CU; Pedersen LB; Larsen MT; Geisler CH; Hutchings M; Jerkeman M; Grønbæk K
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):572

THE CANNABINOID STUDY – 01: INVESTIGATING THE EFFECTS OF CANNABINOIDS IN INDOLENT LEUKEMIC B‐CELL LYMPHOMA

Melén CM; Merrien M; Wasik AM; Sonnevi K; Junlén H; Christensson B; Sander B; Wahlin BE
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):242

EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH‐RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME

Eskelund CW; Kolstad A; Glimelius I; Räty R; Gjerdrum LR; Sonnevi K; Josefsson P; Nilsson‐Ehle H; Bentzen H; Fagerli U; Kuittinen O; Haaber J; Pedersen LB; Larsen MT; Geisler CH; Hutchings M; Jerkeman M; Grønbæk K
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7

The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016.

Carlsten M; Jädersten M; Hellström A; Littmann K; Melén CM; Junlén HR; Sonnevi K; Ljungman P; Björkstrand B; Wahlin BE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;175(4):614-622

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.

Melén CM; Enblad G; Sonnevi K; Junlén HR; Smedby KE; Jerkeman M; Wahlin BE
Article: THROMBOSIS RESEARCH. 2014;133(5):762-767

Risk factors for recurrent venous thromboembolism in young and middle-aged women.

Ljungqvist M; Sonnevi K; Bergendal A; Holmström M; Kieler H; Lärfars G
Article: THROMBOSIS RESEARCH. 2013;132(2):164-169

Self-reported family history in estimating the risk of hormone, surgery and cast related VTE in women.

Sonnevi K; Bergendal A; Adami J; Lärfars G; Kieler H
Article: BLOOD COAGULATION & FIBRINOLYSIS. 2013;24(5):547-553

Obesity and thrombin-generation profiles in women with venous thromboembolism.

Sonnevi K; Tchaikovski SN; Holmström M; Antovic JP; Bremme K; Rosing J; Lärfars G
Article: THROMBOSIS AND HAEMOSTASIS. 2011;106(5):901-907

Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.

Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
Journal article: BLOOD. 2010;116(21):154

High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18–64 Years After a First Event of VTE

Sonnevi K; Tchaikovski SN; Bremme K; Holmstrom M; Rosing J; Larfars G
Visa fler

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

Smedby KE; Wästerlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Österborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Conference publication: BLOOD. 2022;140:10790

Rituximab Infusion in 30 Minutes' Is Safe and Improves the Flow of Outpatients with Lymphoma Treatment (SPEEDR)

Wahlin BE; Radman T; Ljungqvist M; Sonnevi K
Conference publication: BLOOD. 2021;138:4587

Good Outcome after R-Hyper-CVAD/R-MA in High-Risk Aggressive B-Cell Lymphoma: A Single-Center Experience

Sonnevi K; Ljungqvist M; Joelsson JK; Harrysson S; Wasterlid T; Bernell P; Wahlin B
Preprint: RESEARCH SQUARE. 2020

The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome

Noring K; Carlsten M; Sonnevi K; Wahlin B
Conference publication: BLOOD. 2020;136:3-4

Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project

Jerkeman M; Palsdottir T; Glimelius I; Albertsson-Lindblad A; Weibull C; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Letter: ANNALS OF HEMATOLOGY. 2020;99(3):649-651

Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation.

Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Conference publication: BLOOD. 2019;134:5487

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Melen CM; Merrien M; Wasik A; Sonnevi K; Junlen H-R; Christersson B; Sander B; Wahlin BE
Conference publication: BLOOD. 2018;132:4121

Cannabinoid Receptors and CXCR4 Cross-Talk in Lymphoma Cells

Merrien M; Wasik AM; Melen C; Sonnevi K; Christensson B; Wahlin BE; Sander B
Preprint: SSRN ELECTRONIC JOURNAL. 2018

Morbidity, Mortality and Normality after Autologous Stem-Cell Transplantation for Lymphoma: A Comprehensive, Single-Centre, Population-Based, Real-World Analysis of Patients Transplanted 1994-2016

Carlsten M; Jädersten M; Hellström A; Littmann K; Melén CM; Junlén HR; Sonnevi K; Ljungman P; Björkstrand B; Wahlin B
Conference publication: HAEMATOLOGICA. 2014;99:537

MORTALITY AND CARDIOVASCULAR DISEASE AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM IN YOUNG AND MIDDLE-AGED WOMEN

Ljungqvist M; Sonnevi K; Odeberg J; Holmstrom M; Kieler H; Larfars G
Thesis / dissertation: 2013

Venous thromboembolism in women : risk factors and long term follow-up

Sonnevi, Kristina
Conference publication: BLOOD. 2012;120(21):2250

Obesity Is a Risk Factor for Recurrent Venous Thrombosis in Young and Middle-Aged Women. Results From Tehs-Follow up, a Nested Cohort Study On 1394 Women with VTE

Ljungqvist M; Sonnevi K; Bergendal A; Holmstrom M; Kieler H; Larfars G
Meeting abstract: THROMBOSIS RESEARCH. 2011;127:S140

High BMI is correlated to increased thrombin generation in women, age 18-65 after venous thromboembolism

Sonnevi K; Antovic J; Holmstrom M; Larfars G
Conference publication: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2011;9:632

Thrombin generation profiles and association with obesity and inflammation in women with VTE

Sonnevi K; Tchaikovski S; Holmstrom M; Bremme K; Rosing J; Larfars G
Conference publication: BLOOD. 2010;116(21):72

High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18-64 Years After a First Event of VTE

Sonnevi K; Tchaikovski SN; Bremme K; Holmstrom M; Rosing J; Larfars G

Anställningar

Postdoktorala Studier, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för klinisk forskning o utbildning, Södersjukhuset, Karolinska Institutet, 2013
Läkarexamen, Karolinska Institutet, 1999

Utvalda publikationer

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI